Review of Evidence for Measuring Drug Concentrations of First-Line Antitubercular Agents in Adults

Clinical Pharmacokinetics

Volumn 53, Issue 10, 2014, Pages 873-890

  Wilby, Kyle John ^a   Ensom, Mary H H ^b   Marra, Fawziah ^b  

^a Qatar University ^*  (Qatar)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; MOXIFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CASE REPORT; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; ADULT; BLOOD; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; DIABETES MELLITUS; DRUG MONITORING; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84918794118     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0170-1     Document Type: Review

References (57)

1. WHO. The top 10 causes of death. World Health Organization; 2013. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 6 April 2014.
2. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009 (Publication no. WHO/HTM/TB/2009.411). Geneva: World Health Organization; 2009.
3. WHO. 2008 Tuberculosis facts. World Health Organization; 2008. http://www.who.int/tb/publications/2008/factsheet_april08.pdf. Accessed 10 August 2014.
4. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Eng J Med. 2013;368:745–55.
5. WHO. Global tuberculosis report 2013. World Health Organization; 2013. http://www.who.int/tb/publications/global_report/en/. Accessed 10 August 2014.
6. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet. 2000;39:215–31.
7. Gwilt PR, Nahas R, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20:477–90.
8. Kang J, Lee M. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1–10.
9. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169–83.
10. Begg EJ, Barclay ML, Kirkpatrick CJM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 1999;47:23–30.
11. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit. 2005;27:10–7.
12. Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. Ther Drug Monit. 1998;20:539–42.
13. Peloquin CA. Use of therapeutic drug monitoring in tuberculosis patients. Chest. 2004;126:1722–4.
14. Peloquin CA. Tuberculosis drug serum levels. Clin Infect Dis. 2001;33:584–5.
15. Peloquin A. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med. 1997;18:79–87.
16. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51(7):2546–51.
17. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27–35.
18. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother. 2010;54(3):1068–74.
19. Barroso EC, Pinheiro VG, Facanha MC, Carvalho MR, Moura ME, Campelo CL, et al. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg. 2009;81(2):322–9.
20. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest. 1998;113(5):1178–83.
21. van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H, van der Meer JW, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis. 2002;6(6):497–502.
22. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, et al. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis. 2008;27(6):467–72.
23. Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J. 2011;18(4):225–9.
24. Li J, Burzynski JN, Lee YA, Berg D, Driver CR, Ridzon R, et al. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest. 2004;126(6):1770–6. doi:10.1378/chest.126.6.1770.
25. Heysell SK, Mtabho C, Mpagama S, Mwaigwisya S, Pholwat S, Ndusilo N, et al. Plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob Agents Chemother. 2011;55(12):5819–25.
26. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 2004;48(11):4473–5.
27. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48(12):1685–94.
28. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005;41(4):461–9.
29. Saleri N, Dembele SM, Villani P, Carvalho AC, Cusato M, Bonkoungou V, et al. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. J Antimicrob Chemother. 2012;67(2):469–72.
30. Van Tongeren L, Nolan S, Cook VJ, FitzGerald JM, Johnston JC. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis. 2013;17(2):221–4.
31. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis. 2010;16(10):1546–53.
32. Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat. 2013;2013:129723. doi:10.1155/2013/129723 (Epub 2013 Nov 17).
33. Requena-Mendez A, Davies G, Ardrey A, Jave O, Lopez-Romero SL, Ward SA, et al. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother. 2012;56(5):2357–63.
34. Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildiz L, et al. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients. Int J Tuberc Lung Dis. 2013;17(11):1442–7.
35. Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis. 2004;8(11):1360–7.
36. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy. 2002;22(6):686–95.
37. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43(7):848–54.
38. Narita M, Hisada M, Thimmappa B, Stambaugh J, Ibrahim E, Hollender E, et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis. 2001;32(3):515–7.
39. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003;167(10):1341–7.
40. Mehta JB, Shantaveerapa H, Byrd RP Jr, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest. 2001;120(5):1520–4.
41. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med. 2003;33(5–6):229–34.
42. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy. 2009;29(5):503–10.
43. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50(4):1170–7.
44. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis. 2007;11(9):972–8.
45. Ahmed R, Cooper R, Foisy M, Der E, Kunimoto D. Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection. J Int Assoc Provid AIDS Care. 2012;11(5):273–6.
46. Pea F, Milaneschi R, Baraldo M, Talmassons G, Furlanut M. Isoniazid and its hydrazine metabolite in patients with tuberculosis. Clin Drug Invest. 1999;17(2):145–54.
47. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis. 2005;41(11):1638–47.
48. Fahimi F, Kobarfard F, Tabarsi P, Hemmati S, Salamzadeh J, Baniasadi S. Isoniazid blood levels in patients with pulmonary tuberculosis at a tuberculosis referral center. Chemother. 2011;57(1):7–11.
49. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, et al. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob Agents Chemother. 2013;57(7):3208–13.
50. Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R. Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther. 2012;25(1):83–6.
51. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. N Eng J Med. 1992;327(25):1817–8.
52. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. New Eng J Med. 1995;332(5):336–7.
53. Fahimi F, Tabarsi P, Kobarfard F, Bozorg BD, Goodarzi A, Dastan F, et al. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013;17:1602–6.
54. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Tawanda G. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208:1464–73.
55. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lonnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.
56. Geiseler PJ, Manis RD Jr, Maddux MS. Dosage of antituberculosis drugs in obese patients. Am Rev Respir Dis. 1985;131:944–6.
57. de Vittorio SG, Antonio D, Alessio S, Lorena B, Malincarne L, Giovanni DP, Franco B. Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs. Mediterr J Hematol Infect Dis. 2012;4:e2012007.